Guardian Pharmacy Services (GRDN) to Release Quarterly Earnings on Wednesday

Guardian Pharmacy Services (NYSE:GRDN) is expected to issue its Q4 2025 results after the market closes on Wednesday, March 11th. Analysts expect the company to announce earnings of $0.27 per share and revenue of $390.0410 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, March 11, 2026 at 4:30 PM ET.

Guardian Pharmacy Services Stock Up 1.0%

Shares of Guardian Pharmacy Services stock opened at $34.01 on Wednesday. The company has a market cap of $2.15 billion, a P/E ratio of 53.98 and a beta of 0.86. The firm’s 50 day moving average price is $31.47 and its 200-day moving average price is $29.02. Guardian Pharmacy Services has a 52-week low of $17.78 and a 52-week high of $37.43.

Institutional Trading of Guardian Pharmacy Services

Hedge funds have recently added to or reduced their stakes in the company. Dynamic Technology Lab Private Ltd purchased a new position in Guardian Pharmacy Services in the first quarter valued at $233,000. JPMorgan Chase & Co. grew its position in shares of Guardian Pharmacy Services by 48.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 6,027 shares of the company’s stock valued at $128,000 after acquiring an additional 1,956 shares during the period. Legal & General Group Plc grew its position in shares of Guardian Pharmacy Services by 1,783.1% during the 2nd quarter. Legal & General Group Plc now owns 14,895 shares of the company’s stock valued at $317,000 after acquiring an additional 14,104 shares during the period. Rhumbline Advisers increased its stake in shares of Guardian Pharmacy Services by 121.1% in the 2nd quarter. Rhumbline Advisers now owns 16,174 shares of the company’s stock valued at $345,000 after purchasing an additional 8,860 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new position in Guardian Pharmacy Services in the 2nd quarter worth about $214,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on GRDN shares. Wall Street Zen raised Guardian Pharmacy Services from a “buy” rating to a “strong-buy” rating in a report on Monday, November 17th. Stephens raised their price target on shares of Guardian Pharmacy Services from $35.00 to $36.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 14th. Truist Financial upped their price objective on shares of Guardian Pharmacy Services from $30.00 to $34.00 and gave the company a “buy” rating in a report on Friday, November 14th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Guardian Pharmacy Services in a research note on Monday, December 29th. Four investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.